CY1108895T1 - Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονου - Google Patents
Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονουInfo
- Publication number
- CY1108895T1 CY1108895T1 CY20091100318T CY091100318T CY1108895T1 CY 1108895 T1 CY1108895 T1 CY 1108895T1 CY 20091100318 T CY20091100318 T CY 20091100318T CY 091100318 T CY091100318 T CY 091100318T CY 1108895 T1 CY1108895 T1 CY 1108895T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ostropornation
- prevention
- caused
- treatment
- androgen deprivation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η εφεύρεση αυτή αφορά την χρήση ενός εκλεκτικού ρυθμιστή υποδοχέα οιστρογόνου (SERM) για την παρασκευή μιας φαρμακευτικής σύνθεσης για θεραπεία διεγειρόμενης από στέρηση ανδρογόνου οστεοπόρωσης σε άρρεν υποκείμενο που έχει καρκίνο του προστάτη.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33373401P | 2001-11-29 | 2001-11-29 | |
EP05028100A EP1666033B1 (en) | 2001-11-29 | 2002-11-27 | Prevention and treatment of androgen-deprivation induced osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108895T1 true CY1108895T1 (el) | 2014-07-02 |
Family
ID=23304031
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100699T CY1108174T1 (el) | 2001-11-29 | 2008-07-03 | Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονου |
CY20091100318T CY1108895T1 (el) | 2001-11-29 | 2009-03-23 | Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονου |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100699T CY1108174T1 (el) | 2001-11-29 | 2008-07-03 | Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονου |
Country Status (23)
Country | Link |
---|---|
US (1) | US6899888B2 (el) |
EP (5) | EP1574212A1 (el) |
JP (2) | JP2005515988A (el) |
KR (1) | KR100658110B1 (el) |
CN (2) | CN1679956A (el) |
AT (2) | ATE394099T1 (el) |
AU (2) | AU2002356928B2 (el) |
BR (1) | BR0214801A (el) |
CA (2) | CA2468719C (el) |
CY (2) | CY1108174T1 (el) |
DE (2) | DE60226494D1 (el) |
DK (2) | DK1666033T3 (el) |
EA (1) | EA200400744A1 (el) |
ES (2) | ES2305350T3 (el) |
GE (1) | GEP20094841B (el) |
HK (2) | HK1068104A1 (el) |
HR (1) | HRP20040547A2 (el) |
IL (2) | IL162144A0 (el) |
MX (1) | MXPA04005112A (el) |
PT (2) | PT1460969E (el) |
SI (2) | SI1666033T1 (el) |
TW (1) | TWI315987B (el) |
WO (1) | WO2003047504A2 (el) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040092602A1 (en) * | 1998-05-07 | 2004-05-13 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US20040176470A1 (en) * | 1998-05-07 | 2004-09-09 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US7645898B2 (en) * | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
US7622503B2 (en) * | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US7524866B2 (en) * | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
US8853266B2 (en) * | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
US7332525B2 (en) * | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US20060019989A1 (en) * | 2004-07-21 | 2006-01-26 | Steiner Mitchell S | Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof |
EP1786408A4 (en) * | 2004-09-03 | 2010-07-28 | Hormos Medical Ltd | USE OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR IN THE MANUFACTURE OF A PHARMACEUTICAL PREPARATION USED IN A METHOD OF TREATING OR PREVENTING ENDROGENIC INJURIES |
US20060270641A1 (en) * | 2005-05-31 | 2006-11-30 | Steiner Mitchell S | Method for chemoprevention of prostate cancer |
RU2008122993A (ru) * | 2005-11-09 | 2009-12-20 | Хормос Медикал Лтд. (Fi) | Препаративные формы фиспемифена |
US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
CA2824517A1 (en) * | 2005-11-28 | 2007-05-31 | Gtx, Inc. | Nuclear receptor binding agents |
US8546451B2 (en) | 2005-11-28 | 2013-10-01 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9409856B2 (en) | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US8637706B2 (en) | 2005-11-28 | 2014-01-28 | Gtx, Inc. | Nuclear receptor binding agents |
WO2008099060A2 (en) | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
EP2821385B1 (en) | 2007-02-14 | 2016-07-27 | Hormos Medical Ltd. | Method for the preparation of therapeutically valuable triphenylbutene derivatives |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
PT2222636E (pt) | 2007-12-21 | 2013-07-16 | Ligand Pharm Inc | Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações |
US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
IN2015DN01046A (el) | 2012-07-13 | 2015-06-26 | Gtx Inc | |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US9321712B2 (en) | 2012-10-19 | 2016-04-26 | Fermion Oy | Process for the preparation of ospemifene |
EP3613418A1 (en) | 2014-01-17 | 2020-02-26 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
ES2828305T3 (es) * | 2014-07-24 | 2021-05-26 | Aspen Park Pharmaceuticals Inc | Tratamiento de sofocos y pérdida ósea inducidos por tratamiento de privación de andrógenos utilizando cis-clomifeno |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2464203A (en) | 1943-05-21 | 1949-03-15 | Boots Pure Drug Co Ltd | Manufacture of dienoestrol |
US2465505A (en) | 1944-12-05 | 1949-03-29 | Hoffmann La Roche | Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4 |
US2914562A (en) | 1957-08-06 | 1959-11-24 | Wm S Merrell Co | Amine derivatives of triphenylethanol |
GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
US5491173A (en) | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
US4729999A (en) * | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
AU5851690A (en) * | 1989-07-07 | 1991-02-06 | Endorecherche Inc. | Method of treatment of androgen-related diseases |
GB9126209D0 (en) | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
GB9207437D0 (en) | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
US5468488A (en) * | 1993-06-24 | 1995-11-21 | Wahi; Ashok L. | Electrostatically charged nasal application product and method |
TW303299B (el) * | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
DE19526146A1 (de) * | 1995-07-07 | 1997-01-09 | Schering Ag | Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
IL120262A (en) * | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
US5859045A (en) * | 1996-05-08 | 1999-01-12 | Novo Nordisk A/S Novo Alle | Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate |
US6632447B1 (en) | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US6413533B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
WO1999056739A1 (en) | 1998-05-07 | 1999-11-11 | The University Of Tennessee Research Corporation | A method for chemoprevention of prostate cancer |
US6413534B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
AU3342099A (en) * | 1998-06-16 | 2000-01-05 | Pfizer Products Inc. | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty |
EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
WO2000008001A1 (en) * | 1998-08-07 | 2000-02-17 | Chiron Corporation | Substituted isoxazole as estrogen receptor modulators |
JP2002522380A (ja) * | 1998-08-07 | 2002-07-23 | アンドルシェルシュ・インコーポレイテッド | タイプ33α−ヒドロキシステロイドデヒドロゲナーゼの阻害 |
WO2000074684A1 (en) * | 1999-06-04 | 2000-12-14 | The General Hospital Corporation | Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
EP1246814B1 (en) * | 1999-12-30 | 2005-02-16 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
GB0012291D0 (en) * | 2000-05-23 | 2000-07-12 | Astrazeneca Ab | Pharmaceutical combination |
WO2002002099A1 (en) * | 2000-07-05 | 2002-01-10 | Astrazeneca Ab | Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition |
-
2002
- 2002-11-27 EP EP05006610A patent/EP1574212A1/en not_active Withdrawn
- 2002-11-27 CA CA2468719A patent/CA2468719C/en not_active Expired - Fee Related
- 2002-11-27 DK DK05028100T patent/DK1666033T3/da active
- 2002-11-27 GE GEAP20028274A patent/GEP20094841B/en unknown
- 2002-11-27 AT AT02804417T patent/ATE394099T1/de active
- 2002-11-27 EP EP05028100A patent/EP1666033B1/en not_active Expired - Lifetime
- 2002-11-27 CN CNA2005100638704A patent/CN1679956A/zh active Pending
- 2002-11-27 SI SI200230801T patent/SI1666033T1/sl unknown
- 2002-11-27 KR KR1020047008234A patent/KR100658110B1/ko not_active IP Right Cessation
- 2002-11-27 CN CNB028276930A patent/CN100548283C/zh not_active Expired - Fee Related
- 2002-11-27 DE DE60226494T patent/DE60226494D1/de not_active Expired - Lifetime
- 2002-11-27 EP EP02804417A patent/EP1460969B1/en not_active Expired - Lifetime
- 2002-11-27 ES ES02804417T patent/ES2305350T3/es not_active Expired - Lifetime
- 2002-11-27 PT PT02804417T patent/PT1460969E/pt unknown
- 2002-11-27 BR BR0214801-3A patent/BR0214801A/pt not_active Application Discontinuation
- 2002-11-27 CA CA002537913A patent/CA2537913A1/en not_active Abandoned
- 2002-11-27 DK DK02804417T patent/DK1460969T3/da active
- 2002-11-27 JP JP2003548765A patent/JP2005515988A/ja active Pending
- 2002-11-27 DE DE60230687T patent/DE60230687D1/de not_active Expired - Lifetime
- 2002-11-27 MX MXPA04005112A patent/MXPA04005112A/es active IP Right Grant
- 2002-11-27 WO PCT/US2002/036136 patent/WO2003047504A2/en active Application Filing
- 2002-11-27 EP EP08172485A patent/EP2098247A3/en not_active Withdrawn
- 2002-11-27 IL IL16214402A patent/IL162144A0/xx unknown
- 2002-11-27 AT AT05028100T patent/ATE418972T1/de active
- 2002-11-27 EP EP07111247A patent/EP1862165A3/en not_active Withdrawn
- 2002-11-27 EA EA200400744A patent/EA200400744A1/ru unknown
- 2002-11-27 PT PT05028100T patent/PT1666033E/pt unknown
- 2002-11-27 SI SI200230705T patent/SI1460969T1/sl unknown
- 2002-11-27 ES ES05028100T patent/ES2319785T3/es not_active Expired - Lifetime
- 2002-11-27 US US10/305,363 patent/US6899888B2/en not_active Expired - Fee Related
- 2002-11-27 AU AU2002356928A patent/AU2002356928B2/en not_active Ceased
- 2002-12-16 TW TW091136262A patent/TWI315987B/zh not_active IP Right Cessation
-
2004
- 2004-06-15 HR HR20040547A patent/HRP20040547A2/xx not_active Application Discontinuation
-
2005
- 2005-02-22 HK HK05101489A patent/HK1068104A1/xx not_active IP Right Cessation
- 2005-04-07 JP JP2005110874A patent/JP2005247862A/ja active Pending
-
2006
- 2006-12-05 HK HK06113366.3A patent/HK1092066A1/xx not_active IP Right Cessation
-
2008
- 2008-07-03 CY CY20081100699T patent/CY1108174T1/el unknown
- 2008-07-15 AU AU2008203121A patent/AU2008203121A1/en not_active Abandoned
-
2009
- 2009-03-23 CY CY20091100318T patent/CY1108895T1/el unknown
-
2010
- 2010-06-27 IL IL206646A patent/IL206646A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108895T1 (el) | Προληψη και θεραπεια της οστεοπορωσης που προκαλειται απο τη στερηση ανδρογονου | |
NO20024610D0 (no) | Synergistiske metoder og blandinger for behandling av kreft | |
SE9901272D0 (sv) | New improved formulation | |
PT1286671E (pt) | Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan | |
EP1446114A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OSTEOPOROSIS | |
HK1068551A1 (en) | Substituted benzimidazole compounds and their use for the treatment of cancer | |
ATE414512T1 (de) | Kombinationstherapie zur behandlung von krebs | |
EP1379242A4 (en) | METHOD OF TREATING CANCERS AND APPROPRIATE COMPOSITIONS | |
MXPA03008582A (es) | Agentes y metodos para tratamiento de cancer. | |
IL145397A0 (en) | Compositions and methods for treatment of cancer | |
NO20024735D0 (no) | Anvendelse av fulvestrant for behandling av resistent brystcancer | |
PL368035A1 (en) | Compositions and methods for the treatment of cancer | |
BR0111785A (pt) | Composições e métodos para tratamento de candidìase | |
EP1576113A4 (en) | TUMOR ANTIGENS BFA4 AND BCY1 FOR PREVENTING AND / OR TREATING CANCER | |
AU2002360454A8 (en) | Methods and compositions for treating cancer | |
IL160816A0 (en) | Compositions and methods for treatment of cancer | |
DK1379242T3 (da) | Fremgangsmåde til behandling af cancer og sammensætninger til anvendelse derved | |
EP1379538A4 (en) | RIBOZYMES INHIBITING ACE EXPRESSION AND METHODS OF TREATING CANCER BASED ON THESE RIBOZYMES |